Comparison of Surrogate Kidney End Points for Clinical Trials in PKD
Anahita Noruzi(Erasmus MC), Ron T. Gansevoort(University Medical Center Groningen), Dorien J.M. Peters(Leiden University Medical Center), Laixi Xue(Erasmus MC), Tom Nijenhuis(Radboud University Nijmegen), Ewout J. Hoorn(Erasmus MC), Mahdi Salih(Erasmus MC), Joost P.H. Drenth(Amsterdam Neuroscience), Maatje D.A. van Gastel(University Medical Center Groningen), H. Siebe Spijker(Leiden University Medical Center), Thomas Bais(University Medical Center Groningen), Esther Meijer(University Medical Center Groningen)
Cited by 0
Related Papers
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts
|Kidney International|2011|1.1k
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|Intensive Care Medicine|2014|1k